AFM
VIGL

Anson Funds Management’s Vigil Neuroscience VIGL Stock Holding History

Anson Funds Management’s Portfolio VIGL Stock Details VIGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-207,016
Closed -$700K – 214
2023
Q4 		$700K Buy
+207,016
New +$1.07M 0.09% 115

Other funds holding VIGL

AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
NV
Northpond Ventures Bethesda, Maryland $43.7M AUM 27.27% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Anson Funds Management's VIGL Position: Q1 2024 in Review

Anson Funds Management sold out of Vigil Neuroscience (VIGL) in Q1 2024, closing a stake of 207,016 shares — an estimated $700K sold.

Anson Funds Management first reported a position in VIGL in Q4 2023 and held it in 1 quarter. The position peaked at $700K in Q4 2023. 54 funds tracked by Wall St. Rank hold VIGL as of Q1 2024.

  • Anson Funds Management reported no remaining Vigil Neuroscience position as of Q1 2024 after selling out during the quarter.
  • Anson Funds Management sold 207,016 Vigil Neuroscience shares in Q1 2024, an estimated $700K.
  • Anson Funds Management first reported a position in Vigil Neuroscience in Q4 2023 and held it in 1 quarter.
  • Anson Funds Management's Vigil Neuroscience position peaked at $700K in Q4 2023.
  • 54 funds tracked by Wall St. Rank held Vigil Neuroscience as of Q1 2024.

Based on Anson Funds Management's 13F filing for Q1 2024, filed 14 May 2024.